• Top
  • Medical
  • Development of a novel therapeutic drug, TMS-007, for acute cerebral infarction

Development of a novel therapeutic drug, TMS-007, for acute cerebral infarction


update:2020/06/16
NEXT
PREV
Features and Uniqueness
  • The currently approved fibrynolytic therapy is only alteplase, but the use of it has been limited to 5% of patients with acute cerebral infarction due to possible side effects including hemorrhagic infarction that may be life-threatening. TMS-007 is a novel drug that has both fibrynolytic activity and brain protective effects. The aim of this project is to perform a clinical trial of this drug and to further achieve a commercial-based clinical use. We believe that this drug would contribute significantly in the treatment of acute cerebral infarction.
Keywords

Researchers

Administrative Staff

Teiji Tominaga, Professor
Doctor of Medicine